BridgeBio Pharma, Inc. Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest
BridgeBio Pharma, Inc. (BBIO) reported Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest of -$13.18 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest · last filed 2020-11-05
- BridgeBio Pharma, Inc. net income (loss) attributable to nonredeemable noncontrolling interest for the quarter ending 2020-09-30 was -$13.18M.
- BridgeBio Pharma, Inc. net income (loss) attributable to nonredeemable noncontrolling interest for the quarter ending 2020-06-30 was -$13.60M.
- BridgeBio Pharma, Inc. net income (loss) attributable to nonredeemable noncontrolling interest for the quarter ending 2020-03-31 was -$11.37M.
- BridgeBio Pharma, Inc. net income (loss) attributable to nonredeemable noncontrolling interest for the quarter ending 2019-12-31 was -$9.93M.
- BridgeBio Pharma, Inc. net income (loss) attributable to nonredeemable noncontrolling interest for fiscal 2019 was -$25.12M.
- BridgeBio Pharma, Inc. net income (loss) attributable to nonredeemable noncontrolling interest for fiscal 2018 was -$26.17M.
- BridgeBio Pharma, Inc. net income (loss) attributable to nonredeemable noncontrolling interest for fiscal 2017 was -$10.51M.
| Period end | Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2020-09-30 | -$13.18M 10-Q · filed 2020-11-05 | -$26.78M derived: sum of 2 quarters · filed 2020-11-05 | -$38.15M derived: sum of 3 quarters · filed 2020-11-05 | -$48.07M derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | -$13.60M 10-Q · filed 2020-11-05 | -$24.97M derived: sum of 2 quarters · filed 2020-11-05 | -$34.89M derived: sum of 3 quarters · filed 2020-11-05 | -$34.94M derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-03-31 | -$11.37M 10-Q · filed 2020-11-05 | -$21.29M derived: sum of 2 quarters · filed 2020-11-05 | -$21.34M derived: sum of 3 quarters · filed 2020-11-05 | -$29.02M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-12-31 | -$9.93M derived: 10-K 12 month − 3 quarters · filed 2020-03-03 | -$9.97M derived: sum of 2 quarters · filed 2020-03-03 | -$17.66M derived: sum of 3 quarters · filed 2020-03-03 | -$25.12M 10-K · filed 2020-03-03 |
| 2019-09-30 | -$49.00K 10-Q · filed 2019-11-08 | -$7.73M derived: sum of 2 quarters · filed 2019-11-08 | -$15.20M derived: sum of 3 quarters · filed 2019-11-08 | |
| 2019-06-30 | -$7.68M 10-Q · filed 2019-11-08 | -$15.15M derived: sum of 2 quarters · filed 2019-11-08 | ||
| 2019-03-31 | -$7.46M 10-Q · filed 2019-11-08 | |||
| 2018-12-31 | -$26.17M 10-K · filed 2020-03-03 | |||
| 2017-12-31 | -$10.51M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |